AI-Generated Content Disclosure (CA AB 3030) — This article was researched and drafted by Mentis Intelligence, an AI system operated by Carlo P. Honrado M.D., Inc. It is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Its material claims are checked against cited public sources under the governed publishing policy. No physician authorship or individualized clinical judgment is claimed. To speak with a human member of our team, please contact us online or call our office directly.

Why Is the July 2026 TXA Plastic Surgery Survey Important for Facial Surgery Patients?

The July 2026 publication of an international JPRAS Open survey has put tranexamic acid, or TXA, in the spotlight as plastic surgeons worldwide report broader use of the medication to help reduce bleeding, bruising, and swelling in aesthetic and reconstructive procedures, while also noting that dosing, delivery routes, and clot-risk screening still need stronger standardization.

For patients considering facial plastic surgery in Beverly Hills, Century City, or the greater Los Angeles area, the survey is relevant because TXA is increasingly discussed in procedures where bruising and swelling are visible during early recovery, including facelift surgery, neck lift surgery, eyelid surgery, rhinoplasty, and facial fat transfer.

What Did the July 2026 TXA Survey Report?

Tranexamic acid is a medication that helps stabilize blood clots by reducing the breakdown of fibrin, a protein involved in clot formation. In plastic surgery, TXA is used to reduce bleeding and bruising; it is not a blood thinner.

The newly published study, titled “International survey on the use of tranexamic acid in plastic surgery—Current practices and perspectives,” appeared in JPRAS Open in July 2026 and examined how plastic surgeons internationally are using TXA in both aesthetic and reconstructive settings. According to JPRAS Open on ScienceDirect, the survey examines “the use of tranexamic acid in plastic surgery” and focuses on “current practices and perspectives.” That wording is important because the study is a survey of current practice patterns, not a universal treatment guideline.

The development matters for facial plastic surgery patients because TXA is increasingly discussed in connection with procedures where bruising and swelling can affect early social recovery, including:

1. Facelift surgery and neck lift surgery
2. Eyelid surgery, or blepharoplasty
3. Rhinoplasty
4. Facial fat transfer
5. Other aesthetic and reconstructive procedures involving soft-tissue dissection

The study’s title itself describes the research focus as “current practices and perspectives,” reflecting that TXA use is already occurring in real-world plastic surgery, but protocols are not yet uniform across surgeons or centers.

Why Is TXA Relevant to Facial Plastic Surgery Patients?

TXA refers to tranexamic acid, an antifibrinolytic medication that helps prevent premature clot breakdown. In surgery, the goal is to support hemostasis, which means control of bleeding.

For facial procedures, even small differences in bleeding and bruising can matter because swelling and discoloration occur in highly visible areas. The July 2026 survey is relevant to prospective patients because it gives a contemporary snapshot of how surgeons are incorporating TXA into perioperative care and where uncertainty remains.

According to the JPRAS Open survey, surgeons report using TXA with the perceived aim of reducing:

• Intraoperative bleeding
• Postoperative bruising
• Postoperative swelling
• The need to manage a less clear surgical field

For patients, these points may translate into a more informed preoperative conversation rather than a guaranteed recovery change. Individual healing, surgical technique, health history, and the extent of the procedure all remain important.

The survey also reinforces a key safety point: TXA decisions should be individualized. Patients with a personal or family history of deep vein thrombosis, pulmonary embolism, thrombophilia, stroke, cardiovascular disease, or certain medication exposures may need additional screening or may not be candidates for TXA.

How Is TXA Being Used in Plastic Surgery?

A route of administration is the way a medication is delivered into or onto the body. The survey reports that surgeons use TXA through several routes.

Commonly discussed routes include:

1. Intravenous TXA: Medication delivered through an IV during surgery.
2. Local TXA: Medication mixed with local anesthetic solution and injected into the surgical area.
3. Topical TXA: Medication applied directly to the surgical field.

According to the JPRAS Open publication, routes and dosing vary internationally, and that variation is one reason the authors highlight the need for more standardized, evidence-based recommendations.

This is especially important in facial plastic surgery because procedures can differ substantially in anatomy, extent, operative time, and expected bruising. For example, TXA use in rhinoplasty may differ from TXA use in facelift and neck lift surgery, blepharoplasty, or facial fat transfer. Procedure-specific planning may also differ when facial rejuvenation includes SMAS techniques, deep plane facelift concepts, platysmaplasty, upper eyelid blepharoplasty, lower eyelid blepharoplasty, or structural rhinoplasty.

Patients may also hear credentials and training terms during research, including board-certified, fellowship-trained, FACS, ABFPRS, and facial plastic and reconstructive surgery. These terms relate to physician education, certification, and surgical training, but they do not replace an individualized consultation.

What Numbers Help Put This Development in Context?

Several concrete figures from the current research landscape help define the timeline and scope of the TXA discussion:

1. The international TXA survey was published in July 2026, making it a current addition to the plastic surgery literature, according to JPRAS Open.
2. The survey evaluates TXA use across 3 primary administration routes: intravenous, topical, and local injection, according to the JPRAS Open study.
3. The survey specifically applies to 2 broad categories of plastic surgery: aesthetic and reconstructive surgery, according to the article.
4. For facial plastic surgery patients, the findings are relevant to at least 4 commonly discussed procedure categories: facelift/neck lift, eyelid surgery, rhinoplasty, and fat transfer.
5. The study tracks 4 key practice domains: how often TXA is used, which procedures involve TXA, which routes are used, and what doses are selected.
6. The study identifies 2 major perceived benefit categories: reduced bleeding and reduced bruising/swelling, according to the survey summary.
7. The study highlights 1 central safety concern repeatedly associated with TXA discussions: possible clotting risk in susceptible patients.
8. According to MedlinePlus, tranexamic acid tablets are commonly taken 3 times a day for up to 5 days for an FDA-approved heavy menstrual bleeding indication; surgical use is a separate clinical context and should be discussed with a physician.
9. According to the FDA-approved label for tranexamic acid injection, each 10 mL vial of tranexamic acid injection contains 1,000 mg of tranexamic acid, or 100 mg/mL.
10. According to the American Society of Plastic Surgeons, there were 26.2 million surgical and minimally invasive cosmetic and reconstructive procedures performed in the United States in 2022, illustrating the broad scale of plastic surgery care in which perioperative bleeding-control strategies may be studied.
11. According to the American Society of Plastic Surgeons 2023 procedural statistics, rhinoplasty was among the top cosmetic surgical procedures in the United States, with nearly 174,000 procedures reported in 2023.
12. According to the American Society of Plastic Surgeons 2023 report, eyelid surgery also remained common, with more than 120,000 procedures reported in 2023.
13. According to the Cleveland Clinic, many blepharoplasty patients return to usual activities in about 10 to 14 days, although healing varies by individual and procedure.
14. According to the American Society of Plastic Surgeons rhinoplasty recovery guidance, initial swelling after rhinoplasty may improve within a few weeks, while nasal refinement can continue for up to 1 year or longer.

Separately, professional education in facial plastic surgery remains active in 2026. The 2026 ISPRES Annual Congress, listed by the International Society of Plastic Regenerative Surgeons, reflects ongoing international exchange around regenerative and aesthetic surgery topics. Meanwhile, the Facial Plastic Surgery World Congress 2026 has been promoted as a 3-day global facial plastic surgery event, underscoring continued attention to facial procedure advances.

What Do Medical Sources Say About TXA and Safety?

The July 2026 survey describes favorable surgeon experiences but also notes caution around clotting risk. That distinction is important: a medication can be useful in selected patients while still requiring careful screening.

According to MedlinePlus, patients should tell clinicians if they have ever had a blood clot and should disclose “medical and family history” before tranexamic acid is used. MedlinePlus also explains that tranexamic acid “is in a class of medications called antifibrinolytics,” which is the medication category relevant to clot stabilization.

The U.S. Food and Drug Administration regulates TXA-containing medications for specific indications. According to the FDA label for tranexamic acid injection, “Tranexamic acid injection is an antifibrinolytic indicated in patients with hemophilia for short-term use” around dental extraction. That FDA wording does not mean the same indication applies to aesthetic facial surgery; it reinforces that approved labeling is indication-specific and that off-label perioperative use should be clinician-directed.

Broader medical literature has long described TXA as an antifibrinolytic drug used to reduce bleeding in surgical and trauma settings. According to the National Library of Medicine’s PubMed database, TXA has been studied across many surgical specialties, including randomized trials and meta-analyses evaluating blood loss and transfusion outcomes. These studies help explain why TXA is familiar to many surgical teams, while still leaving procedure-specific questions for facial plastic surgery.

According to StatPearls via the National Library of Medicine, tranexamic acid is used to treat or prevent bleeding by inhibiting fibrinolysis, the process that dissolves blood clots. This mechanism helps explain why TXA may be relevant to surgical bleeding control but also why patient selection and clot-risk screening matter.

For surgery-specific decisions, professional-society context matters. According to the American Society of Plastic Surgeons, patient safety includes careful review of health history, medications, and surgical risk factors. According to the American Academy of Facial Plastic and Reconstructive Surgery, facial plastic and reconstructive surgery is a specialty focused on the face, head, and neck, where physician training, board certification, and patient-specific planning are central.

The key patient takeaway is not that every facial surgery should include TXA. Rather, the survey suggests TXA is now common enough that patients can reasonably ask whether it is part of a surgeon’s protocol and how safety screening is handled.

What Questions Should Patients Ask Before Surgery?

Prospective facial plastic surgery patients can use the July 2026 survey as a conversation starter. Helpful questions include:

1. Will TXA be used during my procedure?
   Ask whether TXA is part of the surgical plan for facelift, neck lift, eyelid surgery, rhinoplasty, or facial fat transfer.

2. Which route would be used?
   TXA may be given intravenously, mixed into local anesthetic, or applied topically.

3. Why is TXA appropriate or not appropriate for me?
   The decision may depend on health history, procedure type, medications, and risk factors.

4. How do you screen for clotting risk?
   Patients should disclose personal and family history of DVT, pulmonary embolism, stroke, thrombophilia, heart disease, hormone therapy, and smoking.

5. What recovery changes are realistic?
   TXA may be used with the goal of reducing bruising or swelling, but it does not guarantee a specific appearance or timeline.

6. How does TXA fit with the overall recovery plan?
   TXA does not replace postoperative instructions, blood pressure control, medication review, cold compress guidance, head elevation, activity restrictions, or follow-up visits.

What Does This Mean for Recovery Expectations?

Recovery expectations after facial plastic surgery should remain individualized. TXA may be one part of perioperative planning, but it does not replace meticulous surgical technique, blood pressure control, medication review, postoperative instructions, and patient-specific healing factors.

Bruising and swelling are normal after many facial procedures. The July 2026 survey suggests many surgeons perceive TXA as helpful for reducing those issues, but the study also shows that the field still needs clearer standards for dose, timing, route, and patient selection.

For patients, the most practical implication is transparency. TXA should be discussed in the same way as anesthesia, incision placement, postoperative compression, medication restrictions, and return-to-activity timelines.

General recovery ranges vary by procedure. Many patients are told to expect visible bruising or swelling for 1 to 2 weeks after blepharoplasty, rhinoplasty, or facial rejuvenation procedures, with swelling continuing to refine over additional weeks or months depending on the operation and the individual. These ranges are general educational context only and should not be interpreted as a personal recovery prediction.

According to ASPS rhinoplasty recovery information, swelling after rhinoplasty can take up to 1 year to fully refine. According to Cleveland Clinic blepharoplasty recovery information, common early recovery after eyelid surgery is often measured in 10 to 14 days, though this varies by patient.

FAQ

What is tranexamic acid?

Tranexamic acid is an antifibrinolytic medication that helps stabilize clots by reducing fibrin breakdown. In plastic surgery, it may be used to reduce bleeding, bruising, and swelling.

Is TXA a blood thinner?

No. TXA is not a blood thinner. It works in the opposite direction by helping prevent premature clot breakdown, which can reduce bleeding in selected clinical settings.

Is TXA used in facial plastic surgery?

Yes, the July 2026 JPRAS Open survey reports TXA use across aesthetic and reconstructive plastic surgery, including procedure types relevant to facial surgery such as facelift, neck lift, eyelid surgery, rhinoplasty, and fat transfer.

Does TXA guarantee less bruising after surgery?

No. TXA may be used with the goal of reducing bruising and swelling, but no medication can guarantee a specific recovery. Individual results vary.

Who should be cautious about TXA?

Patients with a history of blood clots, pulmonary embolism, stroke, thrombophilia, cardiovascular disease, or certain medication risks should discuss these factors with a qualified physician before TXA is considered.

Why Is This Development Important in 2026?

The July 2026 international survey is important because it documents a real-world trend: TXA is increasingly part of plastic surgery discussions, yet protocols vary. That combination—widespread use plus incomplete standardization—makes patient education especially important.

As facial plastic surgery continues to emphasize refined recovery, reduced bruising, and individualized planning, TXA is likely to remain a topic in preoperative consultations. The best use of the new survey is not as a blanket endorsement, but as a prompt for better questions about benefits, risks, route, dose, and patient selection.

For patients researching facial procedures in Beverly Hills, Century City, and Los Angeles, TXA is best understood as one possible perioperative tool—not a stand-alone recovery solution. A complete surgical plan may include procedure selection, anesthesia planning, medication review, risk screening, incision strategy, postoperative instructions, and follow-up care.

This article was produced by Mentis Intelligence for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual results vary. New techniques and devices should be discussed with a qualified physician. For a consultation with Dr. Carlo Honrado MD, FACS, contact (310) 286-0043 or visit drhonrado.com/contact.
Content generated by AI (Mentis Intelligence) per California AB 3030 disclosure requirement.

For patients in Beverly Hills, Century City, and the greater Los Angeles area who want to discuss facial plastic surgery options, visit the practice’s contact page.

Stay Connected

Questions about your care options?

Our team is here to answer your questions and guide you toward the right next step — in a private, unhurried consultation.